National Academies Press: OpenBook
Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×

THE RESISTANCE PHENOMENON IN MICROBES AND INFECTIOUS DISEASE VECTORS

Implications for Human Health and Strategies for Containment

Workshop Summary

Stacey L. Knobler, Stanley M. Lemon, Marjan Najafi, and Tom Burroughs, Editors

Forum on Emerging Infections

Board on Global Health

INSTITUTE OF MEDICINE OF THE NATIONAL ACADEMIES

THE NATIONAL ACADEMIES PRESS
Washington, D.C. www.nap.edu

Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×

THE NATIONAL ACADEMIES PRESS
500 Fifth Street N.W.Washington, DC 20001

NOTICE: The project that is the subject of this workshop summary was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine.

Support for this project was provided by the U.S. Department of Health and Human Services’ National Institutes of Health, Centers for Disease Control and Prevention, and Food and Drug Administration; U.S. Agency for International Development; U.S. Department of Defense; U.S. Department of State; U.S. Department of Veterans Affairs; U.S. Department of Agriculture; American Society for Microbiology; Burroughs Wellcome Fund; Eli Lilly & Company; Pfizer; GlaxoSmithKline; and Wyeth-Ayerst Laboratories.

This report is based on the proceedings of a workshop that was sponsored by the Forum on Emerging Infections. It is prepared in the form of a workshop summary by and in the name of the editors, with the assistance of staff and consultants, as an individually authored document. Sections of the workshop summary not specifically attributed to an individual reflect the views of the editors and not those of the Forum on Emerging Infections. The content of those sections is based on the presentations and the discussions that took place during the workshop.

International Standard Book Number: 0-309-08854-2

Library of Congress Number 2003005451

Additional copies of this report are available for sale from the
National Academies Press,
500 Fifth Street, N.W., Box 285, Washington, DC 20055; (800) 624-6242 or (202) 334-3313 (in the Washington metropolitan area); Internet, http://www.nap.edu.

For more information about the Institute of Medicine, visit the IOM home page at: www.iom.edu.

Copyright 2003 by the National Academy of Sciences. All rights reserved.

Printed in the United States of America.

The serpent has been a symbol of long life, healing, and knowledge among almost all cultures and religions since the beginning of recorded history. The serpent adopted as a logotype by the Institute of Medicine is a relief carving from ancient Greece, now held by the Staatliche Museen in Berlin.

Cover: The background for the cover of this workshop summary is a photograph of a batik designed and printed specifically for the Malaysian Society of Parasitology and Tropical Medicine. The print contains drawings of various parasites and insects; it is used with the kind permission of the Society.

Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×

“Knowing is not enough; we must apply. Willing is not enough; we must do.”

—Goethe

INSTITUTE OF MEDICINE OF THE NATIONAL ACADEMIES

Shaping the Future for Health

Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×

THE NATIONAL ACADEMIES

Advisers to the Nation on Science, Engineering, and Medicine

The National Academy of Sciences is a private, nonprofit, self-perpetuating society of distinguished scholars engaged in scientific and engineering research, dedicated to the furtherance of science and technology and to their use for the general welfare. Upon the authority of the charter granted to it by the Congress in 1863, the Academy has a mandate that requires it to advise the federal government on scientific and technical matters. Dr. Bruce M. Alberts is president of the National Academy of Sciences.

The National Academy of Engineering was established in 1964, under the charter of the National Academy of Sciences, as a parallel organization of outstanding engineers. It is autonomous in its administration and in the selection of its members, sharing with the National Academy of Sciences the responsibility for advising the federal government. The National Academy of Engineering also sponsors engineering programs aimed at meeting national needs, encourages education and research, and recognizes the superior achievements of engineers. Dr. Wm. A. Wulf is president of the National Academy of Engineering.

The Institute of Medicine was established in 1970 by the National Academy of Sciences to secure the services of eminent members of appropriate professions in the examination of policy matters pertaining to the health of the public. The Institute acts under the responsibility given to the National Academy of Sciences by its congressional charter to be an adviser to the federal government and, upon its own initiative, to identify issues of medical care, research, and education. Dr. Harvey V. Fineberg is president of the Institute of Medicine.

The National Research Council was organized by the National Academy of Sciences in 1916 to associate the broad community of science and technology with the Academy’s purposes of furthering knowledge and advising the federal government. Functioning in accordance with general policies determined by the Academy, the Council has become the principal operating agency of both the National Academy of Sciences and the National Academy of Engineering in providing services to the government, the public, and the scientific and engineering communities. The Council is administered jointly by both Academies and the Institute of Medicine. Dr. Bruce M. Alberts and Dr. Wm. A. Wulf are chair and vice chair, respectively, of the National Research Council.

www.national-academies.org

Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×

FORUM ON EMERGING INFECTIONS

ADEL MAHMOUD (Chair), President,

Merck Vaccines, Whitehouse Station, New Jersey

STANLEY LEMON (Vice-Chair), Dean,

School of Medicine, The University of Texas Medical Branch, Galveston, Texas

DAVID ACHESON, Chief Medical Officer,

Center for Food Safety and Applied Nutrition, Food and Drug Administration, Rockville, Maryland

STEVEN BRICKNER, Research Advisor,

Pfizer Global Research and Development, Pfizer Inc., Groton, Connecticut

GAIL CASSELL, Vice President,

Scientific Affairs, Eli Lilly & Company, Indianapolis, Indiana

GORDON DEFRIESE, Professor of Social Medicine,

University of North Carolina, Chapel Hill, North Carolina

CEDRIC DUMONT, Medical Director,

Department of State and the Foreign Service, Washington, DC

JESSE GOODMAN, Deputy Director,

Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Maryland

RENU GUPTA, Vice President and Head,

U.S. Clinical Research and Development, and

Head,

Global Cardiovascular, Metabolic, Endocrine, and G.I. Disorders, Novartis Corporation, East Hanover, New Jersey

MARGARET HAMBURG, Vice President for Biological Programs,

Nuclear Threat Initiative, Washington, DC

CAROLE HEILMAN, Director,

Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

DAVID HEYMANN, Executive Director,

Communicable Diseases, World Health Organization, Geneva, Switzerland

JAMES HUGHES, Assistant Surgeon General and Director,

National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia

SAMUEL KATZ, Wilburt C. Davison Professor and Chairman Emeritus,

Duke University Medical Center, Durham, North Carolina

PATRICK KELLEY, Colonel, Director,

Department of Defense Global Emerging Infections System, Walter Reed Army Institute of Research, Silver Spring, Maryland

MARCELLE LAYTON, Assistant Commissioner,

Bureau of Communicable Diseases, New York City Department of Health, New York, New York

JOSHUA LEDERBERG,

Raymond and Beverly Sackler Foundation Scholar, The Rockefeller University, New York, New York

Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×

CARLOS LOPEZ, Research Fellow,

Research Acquisitions, Eli Lilly Research Laboratories, Indianapolis, Indiana

LYNN MARKS, Global Head of Infectious Diseases,

GlaxoSmithKline, Collegeville, Pennsylvania

STEPHEN MORSE, Director,

Center for Public Health Preparedness, Columbia University, New York, New York

MICHAEL OSTERHOLM, Director,

Center for Infectious Disease Research and Policy and

Professor,

School of Public Health, University of Minnesota, Minneapolis, Minnesota

GARY ROSELLE, Program Director for Infectious Diseases,

VA Central Office, Veterans Health Administration, Department of Veterans Affairs, Washington, DC

DAVID SHLAES, Executive Vice President for Research and Development,

Idenix, Cambridge, Massachusetts

JANET SHOEMAKER, Director,

Office of Public Affairs, American Society for Microbiology, Washington, DC

P. FREDRICK SPARLING, J. Herbert Bate Professor Emeritus of Medicine, Microbiology, and Immunology,

University of North Carolina, Chapel Hill, North Carolina

MICHAEL ZEILINGER, Infectious Disease Team Leader,

Office of Health and Nutrition, U.S. Agency for International Development, Washington, DC

Liaisons

ENRIQUETA BOND, President,

Burroughs Wellcome Fund, Research Triangle Park, North Carolina

NANCY CARTER-FOSTER, Director,

Program for Emerging Infections and HIV/AIDS, U.S. Department of State, Washington, DC

EDWARD McSWEEGAN,

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

Staff

STACEY KNOBLER, Director,

Forum on Emerging Infections

MARJAN NAJAFI, Research Associate

LAURIE SPINELLI, Project Assistant (until June 2002)

Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×

BOARD ON GLOBAL HEALTH

DEAN JAMISON (Chair), Senior Fellow,

Fogarty International Center, National Institutes of Health, Bethesda, Maryland

YVES BERGEVIN, Chief,

Health Section, UNICEF, New York, New York

PATRICIA DANZON, Professor,

Health Care Systems Department, University of Pennsylvania, Philadelphia, Pennsylvania

RICHARD FEACHEM, Executive Director,

Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland

NOREEN GOLDMAN, Professor,

Woodrow Wilson School of Public and International Affairs, Princeton University, Princeton, New Jersey

MARGARET HAMBURG, Vice President for Biological Programs,

Nuclear Threat Initiative, Washington, DC

GERALD KEUSCH, Director,

Fogarty International Center, National Institutes of Health, Bethesda, Maryland

ARTHUR KLEINMAN, Maude and Lillian Presley Professor of Medical Anthropology/Professor of Psychiatry and Social Medicine,

Harvard Medical School, Boston, Massachusetts

ADEL MAHMOUD, President,

Merck Vaccines, Whitehouse Station, New Jersey

JOHN WYN OWEN, Secretary,

Nuffield Trust, London, United Kingdom

ALLAN ROSENFIELD, Dean,

Mailman School of Public Health, Columbia University, New York, New York

SUSAN SCRIMSHAW, Dean,

School of Public Health, University of Illinois at Chicago, Chicago, Illinois

DONALD BERWICK (IOM Council Liaison), Clinical Professor of Pediatrics and Health Care Policy,

Harvard Medical School, Boston, Massachusetts

DAVID CHALLONER (IOM Foreign Secretary), Vice President for Health Affairs,

University of Florida, Gainesville, Florida

Staff

JUDITH BALE, Director

PATRICIA CUFF, Research Associate

STACEY KNOBLER, Study Director

MARJAN NAJAFI, Research Associate

KATHERINE OBERHOLTZER, Project Assistant

JASON PELLMAR, Project Assistant

MARK SMOLINSKI, Study Director

LAURIE SPINELLI, Project Assistant (until June 2002)

Page viii Cite
Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×
This page in the original is blank.
Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×

Reviewers

All presenters at the workshop have reviewed and approved their respective sections of this report for accuracy. In addition, this workshop summary has been reviewed in draft form by independent reviewers chosen for their diverse perspectives and technical expertise, in accordance with procedures approved by the National Research Council’s Report Review Committee. The purpose of this independent review is to provide candid and critical comments that will assist the Institute of Medicine (IOM) in making the published workshop summary as sound as possible and to ensure that the workshop summary meets institutional standards. The review comments and draft manuscript remain confidential to protect the integrity of the deliberative process.

The Forum and IOM thank the following individuals for their participation in the review process:

Steven Brickner, Pfizer, Inc., Groton, Connecticut

Keith Klugman, Emory University School of Public Health, Atlanta, Georgia

David Ofori-Adjei, University of Ghana, Accra, Ghana

Clyde Thornsberry, Focus Technologies, Inc., Franklin, Tennessee

Mary Wilson, Harvard School of Public Health, Boston, Massachusetts

Kathleen Young, Alliance for Prudent Use of Antibiotics, Boston, Massachusetts

Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×

The review of this report was overseen by Melvin Worth, M.D., Scholar-in-Residence, the National Academies, who was responsible for making certain that an independent examination of this report was carried out in accordance with institutional procedures and that all review comments were carefully considered. Responsibility for the final content of this report rests entirely with the editors and individual authors.

Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×

Preface

The Forum on Emerging Infections was created in 1996 in response to a request from the Centers for Disease Control and Prevention and the National Institutes of Health. The goal of the Forum is to provide structured opportunities for representatives from academia, industry, professional and interest groups, and government1 to examine and discuss scientific and policy issues that are of shared interest and that are specifically related to research and prevention, detection, and management of emerging infectious diseases. In accomplishing this task, the Forum provides the opportunity to foster the exchange of information and ideas, identify areas in need of greater attention, clarify policy issues by enhancing knowledge and identifying points of agreement, and inform decision makers about science and policy issues. The Forum seeks to illuminate issues rather than resolve them directly; hence, it does not provide advice or recommendations on any specific policy initiative pending before any agency or organization. Its strengths are the diversity of its membership and the contributions of individual members expressed throughout the activities of the Forum.

1  

Representatives of federal agencies serve in an ex officio capacity. An ex officio member of a group is one who is a member automatically by virtue of holding a particular office or membership in another body.

Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×

ABOUT THE WORKSHOP

Resistance in microbes—bacterial, viral, or protozoan—to therapeutics is neither surprising nor new. It is, however, an increasing challenge as drug resistance accumulates and accelerates, even as the drugs for combating infections are reduced in power and number. Today some strains of bacterial and viral infections are treatable with only a single drug; some no longer have effective treatments. The disease burden from multi-drug-resistant strains of tuberculosis, malaria, hepatitis, and HIV is growing in both developed and developing countries.

Infections caused by resistant microbes may fail to respond to treatment, resulting in prolonged illness and greater risk of death. Treatment failures also lead to longer periods of infection, which increase the numbers of infected people moving into the community and thus expose the general population to the risk of contracting a resistant strain of infection. When infections become resistant to first-line antimicrobials,2 treatment has to be switched to second- or third-line drugs, which are nearly always much more expensive and sometimes more toxic as well. In many countries, the high cost of such replacement drugs is prohibitive, with the result that some diseases can no longer be treated in areas where resistance to first-line drugs is widespread. Most alarming of all are diseases where resistance is developing for virtually all currently available drugs. Even if the pharmaceutical industry were to step up efforts to develop new replacement drugs immediately, current trends suggest some diseases will have no effective therapies within the next ten years.

More recently, the challenges of resistance are compounded by growing concerns about the possible use of biological weapons leading to large-scale disease outbreak or exposure. The ability to respond effectively to such exposures could be significantly compromised by the introduction of drug-resistant pathogens. The use of prophylactic drugs or therapies on large populations may also contribute to the development of drug resistance and thus increase both the immediate and longer-term challenges of treating infectious diseases.

A number of trends in human behavior increasingly contribute to the emergence of resistance to antimicrobial agents. Host behaviors such as noncompliance with recommended treatment and self-medication are among the most complicit problems associated with the development of resistance. However, the duration of therapy for most acute infections has

2  

In this report, antibiotics are defined as substances (not limited to those produced from microorganisms) that can kill or inhibit the growth of bacteria, while antimicrobials are substances that destroy or inhibit the growth of pathogenic groups of microorganisms, including bacteria, viruses, protozoa, and fungi.

Page xiii Cite
Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×

been determined empirically by treatment outcome, and more research is required on the effect of a reduction of treatment duration on the risk of the emergence of resistance. Other factors contributing to the rise in antimicrobial resistance include over-prescribing by physicians, failure to control the spread of infection in hospitals and long-term care facilities, and the overuse of antimicrobials in animals used for food products.

These trends are currently outpacing scientific discovery to counter resistant pathogens. However, one promising aspect of such factors in the emergence of resistance is their amenability to change, which may be accomplished through public education, appropriate training, political action, and domestic and international regulation.

Beyond the development of resistance in microbes, the ever-increasing resistance of disease vectors to biological and chemical pesticides looms as another complicating factor in efforts to control and eliminate the emergence of infectious diseases. Resistance to insecticides has appeared in the major insect vectors from every genus (e.g., mosquitoes, sand flies, ticks, fleas, and lice). Resistance has developed to every chemical class of insecticide, including microbial drugs and insect growth regulators. Insecticide resistance is predicted to have an increasing and profound effect on the reemergence of most vector-borne diseases. And where resistance has not contributed to disease emergence, it is expected to threaten disease control. Malaria control programs that already face complex challenges presented by multi-drug-resistant strains of the parasite are additionally undermined by vector mosquito populations that show increasing resistance to the pyrethroid-treated bed nets used to reduce malaria transmission.

Resistance is a natural response of microbes and other organisms to selective pressure from antimicrobial and other biological and chemical countermeasures. Adaptive mechanisms in the organisms permit survival and the development of genetic resistance. While the emergence of resistance cannot be eliminated, the rate and extent of its occurrence can be contained. In order to contain the threats posed to human health by resistance, it is important to determine the magnitude and trends of resistance and to define the relative importance of different contributing factors, such as therapeutic, behavioral, economic and social, and health systems factors, as well as veterinary and agricultural misuse. Based on this understanding it may be possible to develop effective methods to contain resistance in different settings.

Through invited presentations and participant discussion, the February 6–7, 2002, Forum workshop explored the causes and consequences of the resistance phenomenon. The Forum discussion also examined the scientific evidence supporting current and potential strategies for containment of resistance in microbes, vectors, and animal and human hosts. Additionally, the methods and measures of a response for industry, federal regulation,

Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×

domestic and international public health, federal and academic research, and the private health care sector were debated.

ORGANIZATION OF WORKSHOP SUMMARY

This workshop summary report is prepared for the Forum membership in the name of the editors, with the assistance of staff and consultants, as a collection of individually authored papers. Sections of the workshop summary not specifically attributed to an individual reflect the views of the editors and not those of the Forum on Emerging Infections’ sponsors or the Institute of Medicine (IOM). The contents of the unattributed sections are based on the presentations and discussions that took place during the workshop.

The workshop summary is organized within chapters as a topic-by-topic description of the presentations and discussions. Its purpose is to present lessons from relevant experience, delineate a range of pivotal issues and their respective problems, and put forth some potential responses as described by the workshop participants. The Summary and Assessment chapter discusses the core messages that emerged from the speakers’ presentations and the ensuing discussions. Chapter 1 is an introduction and overview of the resistance phenomenon. Chapters 2 to 7 begin with overviews provided by the editors, followed by the edited presentations made by the invited speakers. Appendix A is an authored paper describing the consequences of antimicrobial use in agriculture. Appendix B presents the workshop agenda. Appendix C is a list of information resources on resistance. Appendixes D, E, and F contain the executive summaries of three government reports on the topic of antimicrobial resistance. Appendix G presents Forum member and speaker biographies.

Although this workshop summary provides an account of the individual presentations, it also reflects an important aspect of the Forum philosophy. The workshop functions as a dialogue among representatives from different sectors and presents their beliefs on which areas may merit further attention. However, the reader should be aware that the material presented here expresses the views and opinions of those participating in the workshop and not the deliberations of a formally constituted IOM study committee. These proceedings summarize only what participants stated in the workshop and are not intended to be an exhaustive exploration of the subject matter.

ACKNOWLEDGMENTS

The Forum on Emerging Infections and the IOM wish to express their warmest appreciation to the individuals and organizations who gave valu

Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×

able time to provide information and advice to the Forum through participation in the workshop.

The Forum is indebted to the IOM staff who contributed during the course of the workshop and the production of this workshop summary. On behalf of the Forum, we gratefully acknowledge the efforts led by Stacey Knobler, director of the Forum, and Marjan Najafi, research associate, coeditors of this report, who dedicated much effort and time to developing this workshop’s agenda, and for their thoughtful and insightful approach and skill in translating the workshop proceedings and discussion into this workshop summary. We would also like to thank the following IOM staff and consultants for their valuable contributions to this activity: Tom Burroughs, Laurie Spinelli, Judith Bale, Mark Smolinski, Katherine Oberholtzer, Patricia Cuff, Jennifer Otten, Clyde Behney, Bronwyn Schrecker, Sally Stanfield, Sally Groom, Michele de la Menardiere, and Beth Gyorgy.

Finally, the Forum also thanks sponsors that supported this activity. Financial support for this project was provided by the U.S. Department of Health and Human Services’ National Institutes of Health, Centers for Disease Control and Prevention, and Food and Drug Administration; U.S. Department of Defense; U.S. Department of State; U.S. Department of Veterans Affairs; U.S. Department of Agriculture; American Society for Microbiology; Burroughs Wellcome Fund; Eli Lilly & Company; Pfizer; GlaxoSmithKline; and Wyeth-Ayerst Laboratories. The views presented in this workshop summary are those of the editors and workshop participants and are not necessarily those of the funding organizations.

Adel Mahmoud, Chair

Stanley Lemon, Vice-Chair

Forum on Emerging Infections

Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×
This page in the original is blank.
Page xvii Cite
Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×
Page xviii Cite
Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×

3

 

Vector Resistance

 

79

   

Overview,

 

79

   

Insecticide Resistance in Insect Vectors of Human Disease,
Janet Hemingway

 

81

   

Managing the Emergence of Pesticide Resistance in Vectors,
William G. Brogdon

 

88

   

What Is the Role of Insecticide Resistance in the Re-Emergence of Major Arthropod-Borne Diseases?,
Donald R. Roberts and Paul B. Hshieh

 

94

4

 

The Economics of Resistance

 

107

   

Overview,

 

107

   

What Does Economics Have to Offer in the War Against Antimicrobial Resistance?,
Richard D. Smith

 

108

   

Economic Instruments for the Control of Antimicrobial Resistance,
William Jack

 

118

   

Economic Responses to the Problem of Drug Resistance,
Ramanan Laxminarayan

 

121

5

 

Factors Contributing to the Emergence of Resistance

 

130

   

Overview,

 

130

   

Antibiotic Use and Resistance in Developing Countries,
Iruka N. Okeke

 

132

   

Healthcare-Acquired Infections: Hospitals as a Breeding Ground for Antimicrobial Resistance,
Lindsay E. Nicolle

 

139

   

The Use of Antimicrobials in Food-Producing Animals,
Thomas R. Shryock

 

147

6

 

Emerging Tools and Technology for Countering Resistance

 

159

   

Overview,

 

159

   

Evolution of Multiple Mechanisms of Resistance to ß-Lactam Antibiotics,
Dasantila Golemi-Kotra, Sergei Vakulenko, and Shahriar Mobashery

 

160

   

Using Phage Lytic Enzymes to Control Antibiotic-Resistant Pathogenic Bacteria on Mucous Membranes,
Vincent A. Fischetti

 

167

   

Roles for Pharmacokinetics and Pharmacodynamics in Drug Development for Resistant Pathogens,
Jerome J. Schentag and Alan Forrest

 

174

Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×
Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×
This page in the original is blank.
Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×
Page R1
Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×
Page R2
Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×
Page R3
Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×
Page R4
Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×
Page R5
Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×
Page R6
Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×
Page R7
Page viii Cite
Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×
Page R8
Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×
Page R9
Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×
Page R10
Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×
Page R11
Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×
Page R12
Page xiii Cite
Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×
Page R13
Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×
Page R14
Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×
Page R15
Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×
Page R16
Page xvii Cite
Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×
Page R17
Page xviii Cite
Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×
Page R18
Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×
Page R19
Suggested Citation:"Front Matter." Institute of Medicine. 2003. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/10651.
×
Page R20
Next: Summary and Assessment »
The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary Get This Book
×
Buy Paperback | $55.00 Buy Ebook | $43.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

The resistance topic is timely given current events. The emergence of mysterious new diseases, such as SARS, and the looming threat of bioterrorist attacks remind us of how vulnerable we can be to infectious agents. With advances in medical technologies, we have tamed many former microbial foes, yet with few new antimicrobial agents and vaccines in the pipeline, and rapidly increasing drug resistance among infectious microbes, we teeter on the brink of loosing the upperhand in our ongoing struggle against these foes, old and new. The Resistance Phenomenon in Microbes and Infectious Disease Vectors examines our understanding of the relationships among microbes, disease vectors, and human hosts, and explores possible new strategies for meeting the challenge of resistance.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!